La actividad anti-Xa depende del peso en pacientes médicos que reciben tromboprofilaxis con enoxaparina
Authors:
- David JiménezDJDavid Jiménez
- David MartícDMDavid Martíc
- 1 December 2008
- journal article
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 44 (12) , 660-663
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Venous Thromboembolism Prophylaxis in Acutely Ill Hospitalized Medical PatientsChest, 2007
- Anti‐factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years oldBritish Journal of Clinical Pharmacology, 2007
- Efficacy and Safety of Fixed Low-Dose Dalteparin in Preventing Venous Thromboembolism Among Obese or Elderly Hospitalized PatientsArchives of internal medicine (1960), 2005
- Antithrombotic Therapy for Venous Thromboembolic DiseaseChest, 2004
- Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical PatientsCirculation, 2004
- Is laboratory monitoring of low-molecular-weight heparin therapy necessary? YesJournal of Thrombosis and Haemostasis, 2004
- Prevention of venous thromboembolism in medical patients with enoxaparinBlood Coagulation & Fibrinolysis, 2003
- New Onset of Venous Thromboembolism Among Hospitalized Patients at Brigham and Women’s Hospital Is Caused More Often by Prophylaxis Failure Than by Withholding TreatmentChest, 2000
- A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical PatientsNew England Journal of Medicine, 1999
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997